)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Shenzhen Salubris Pharmaceuticals
Shenzhen Salubris Pharmaceuticals (002294) investor relations material
Shenzhen Salubris Pharmaceuticals Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary26 Oct, 2026
Executive summary
9M 2026 revenue rose 15.47% YoY to ¥3.743bn and attributable net income increased 10.93% to ¥644.2m; expanding commercialization of innovative products supported growth.
Q3 revenue grew 13.81% YoY to ¥1.264bn and attributable net income rose 19.24% to ¥257.1m.
Financial highlights
9M adjusted attributable net income, excluding non-recurring gains and losses, was ¥625.2m, up 10.21% YoY; Q3 was ¥224.2m, up 1.68%.
9M operating cash flow was ¥802.5m, up 3.36% YoY; cash and cash equivalents increased ¥147.4m versus a ¥114.9m decrease in the prior-year period.
9M total costs and expenses were ¥3.101bn, including selling expenses of ¥1.477bn, R&D expenses of ¥392.8m and administrative expenses of ¥195.7m.
Key financial ratios and metrics
Basic and diluted EPS were ¥0.23 in Q3, up 21.05% YoY, and ¥0.58 for 9M, up 11.54%.
Weighted average return on equity was 2.93% for Q3 and 7.23% for 9M; total assets were ¥11.233bn, down 0.58% from year-end, and attributable equity was ¥8.666bn, down 2.99%.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Shenzhen Salubris Pharmaceuticals
- Revenue up 16.34% year-over-year, innovative drugs led growth, H-share listing underway.002294
Q2 2026 - Revenue up 8.5%, net profit up 8.3%, innovative drug sales up 47% year-over-year.002294Q4 2025
- Revenue and profit rose double digits year-over-year, with margin and R&D progress supporting growth.002294Q1 2026
- Q3 2025 saw 15.85% revenue growth and 30.19% net profit increase, led by new products.002294Q3 2025
- Net profit rose 6.10% on 4.32% revenue growth, led by new drugs and medical device expansion.002294Q2 2025
- Revenue and net profit rose on strong innovative product growth and robust cash flow.002294Q3 2024
- Revenue up 21.28% and net profit up 1.92% on innovation-driven growth.002294Q2 2024
- 2024 revenue rose 19.22% to ¥4.01B, net profit up 3.71%, with strong R&D and cash dividend.002294Q4 2024
- Patented and new product growth offset generic drug declines, keeping Q1 profit stable.002294Q1 2025
Next Shenzhen Salubris Pharmaceuticals earnings date
Q4 202621 Apr, 2027
Shenzhen Salubris Pharmaceuticals
Next Shenzhen Salubris Pharmaceuticals earnings date
Q4 202621 Apr, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)